These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19675335)

  • 1. Premature release of data from clinical trials of ezetimibe.
    Califf RM; Harrington RA; Blazing MA
    N Engl J Med; 2009 Aug; 361(7):712-7. PubMed ID: 19675335
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 4. Ezetimibe and cancer--an uncertain association.
    Drazen JM; D'Agostino RB; Ware JH; Morrissey S; Curfman GD
    N Engl J Med; 2008 Sep; 359(13):1398-9. PubMed ID: 18765434
    [No Abstract]   [Full Text] [Related]  

  • 5. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amid lingering questions, FDA reprieves LDL cholesterol-lowering medication.
    Mitka M
    JAMA; 2009 Feb; 301(8):813-5. PubMed ID: 19244181
    [No Abstract]   [Full Text] [Related]  

  • 7. Ezetimibe + simvastatin (Merck/Schering-Plough).
    Flores NA
    Curr Opin Investig Drugs; 2004 Sep; 5(9):984-92. PubMed ID: 15503655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials.
    Catapano A; Brady WE; King TR; Palmisano J
    Curr Med Res Opin; 2005 Jul; 21(7):1123-30. PubMed ID: 16004682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
    N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe for lowering blood cholesterol.
    Husereau DR
    Issues Emerg Health Technol; 2003 Sep; (49):1-4. PubMed ID: 14533615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe.
    Mascitelli L; Ravnskov U; Pezzetta F; Goldstein MR
    Angiology; 2009; 60(1):127-8; author reply 129-30. PubMed ID: 19049996
    [No Abstract]   [Full Text] [Related]  

  • 15. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

  • 17. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ezetimib and simvastatin. Cooperation at receptors of cholesterol metabolism].
    MMW Fortschr Med; 2005 Jul; 147(27-28):50. PubMed ID: 16041947
    [No Abstract]   [Full Text] [Related]  

  • 19. [Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
    MMW Fortschr Med; 2004 Oct; 146(44):57. PubMed ID: 15566254
    [No Abstract]   [Full Text] [Related]  

  • 20. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.